L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.
Identifieur interne : 000628 ( PubMed/Corpus ); précédent : 000627; suivant : 000629L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.
Auteurs : Gregory Porras ; Philippe De Deurwaerdere ; Qin Li ; Matteo Marti ; Rudolf Morgenstern ; Reinhard Sohr ; Erwan Bezard ; Michele Morari ; Wassilios G. MeissnerSource :
- Scientific reports [ 2045-2322 ] ; 2014.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects), Animals, Benserazide (adverse effects), Benserazide (pharmacokinetics), Corpus Striatum (drug effects), Corpus Striatum (metabolism), Disease Models, Animal, Dopamine (metabolism), Dopamine Agents (adverse effects), Dopamine Agents (pharmacokinetics), Drug Combinations, Dyskinesias (etiology), Dyskinesias (metabolism), Female, Levodopa (adverse effects), Levodopa (pharmacokinetics), Macaca mulatta, Male, Parkinson Disease (metabolism).
- MESH :
- chemical , adverse effects : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Benserazide, Dopamine Agents, Levodopa.
- chemical , metabolism : Dopamine.
- chemical , pharmacokinetics : Benserazide, Dopamine Agents, Levodopa.
- drug effects : Corpus Striatum.
- etiology : Dyskinesias.
- metabolism : Corpus Striatum, Dyskinesias, Parkinson Disease.
- Animals, Disease Models, Animal, Drug Combinations, Female, Macaca mulatta, Male.
Abstract
L-dopa remains the mainstay treatment for Parkinson's disease (PD), although in later stages, treatment is complicated by L-dopa-induced dyskinesias (LID). Current evidence links LID to excessive striatal L-dopa-derived dopamine (DA) release, while the possibility of a direct involvement of L-dopa itself in LID has been largely ignored. Here we show that L-dopa can alter basal ganglia activity and produce LID without enhancing striatal DA release in parkinsonian non-human primates. These data may have therapeutic implications for the management of advanced PD since they suggest that LID could result from diverse mechanisms of action of L-dopa.
DOI: 10.1038/srep03730
PubMed: 24429495
Links to Exploration step
pubmed:24429495Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.</title><author><name sortKey="Porras, Gregory" sort="Porras, Gregory" uniqKey="Porras G" first="Gregory" last="Porras">Gregory Porras</name><affiliation><nlm:affiliation>1] Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [2] CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [3] Motac neuroscience, Manchester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="De Deurwaerdere, Philippe" sort="De Deurwaerdere, Philippe" uniqKey="De Deurwaerdere P" first="Philippe" last="De Deurwaerdere">Philippe De Deurwaerdere</name><affiliation><nlm:affiliation>1] Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [2] CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Li, Qin" sort="Li, Qin" uniqKey="Li Q" first="Qin" last="Li">Qin Li</name><affiliation><nlm:affiliation>1] Motac neuroscience, Manchester, UK [2] Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China.</nlm:affiliation></affiliation></author><author><name sortKey="Marti, Matteo" sort="Marti, Matteo" uniqKey="Marti M" first="Matteo" last="Marti">Matteo Marti</name><affiliation><nlm:affiliation>Department of Life Sciences and Biotechnology (SVeB), University of Ferrara, Ferrara, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Morgenstern, Rudolf" sort="Morgenstern, Rudolf" uniqKey="Morgenstern R" first="Rudolf" last="Morgenstern">Rudolf Morgenstern</name><affiliation><nlm:affiliation>Institute of Pharmacology and Toxicology, Charité Campus Mitte, Humboldt University, 10117 Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Sohr, Reinhard" sort="Sohr, Reinhard" uniqKey="Sohr R" first="Reinhard" last="Sohr">Reinhard Sohr</name><affiliation><nlm:affiliation>Institute of Pharmacology and Toxicology, Charité Campus Mitte, Humboldt University, 10117 Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name><affiliation><nlm:affiliation>1] Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [2] CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [3] Motac neuroscience, Manchester, UK [4] Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China [5] Service de Neurologie, Centre Expert Parkinson, CHU de Bordeaux, 33076 Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Morari, Michele" sort="Morari, Michele" uniqKey="Morari M" first="Michele" last="Morari">Michele Morari</name><affiliation><nlm:affiliation>Department of Medical Sciences, Section of Pharmacology, University of Ferrara, Ferrara, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Meissner, Wassilios G" sort="Meissner, Wassilios G" uniqKey="Meissner W" first="Wassilios G" last="Meissner">Wassilios G. Meissner</name><affiliation><nlm:affiliation>1] Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [2] CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [3] Service de Neurologie, Centre Expert Parkinson, CHU de Bordeaux, 33076 Bordeaux, France [4] Centre de référence AMS, CHU de Bordeaux, 33076 Bordeaux, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24429495</idno><idno type="pmid">24429495</idno><idno type="doi">10.1038/srep03730</idno><idno type="wicri:Area/PubMed/Corpus">000628</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000628</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.</title><author><name sortKey="Porras, Gregory" sort="Porras, Gregory" uniqKey="Porras G" first="Gregory" last="Porras">Gregory Porras</name><affiliation><nlm:affiliation>1] Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [2] CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [3] Motac neuroscience, Manchester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="De Deurwaerdere, Philippe" sort="De Deurwaerdere, Philippe" uniqKey="De Deurwaerdere P" first="Philippe" last="De Deurwaerdere">Philippe De Deurwaerdere</name><affiliation><nlm:affiliation>1] Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [2] CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Li, Qin" sort="Li, Qin" uniqKey="Li Q" first="Qin" last="Li">Qin Li</name><affiliation><nlm:affiliation>1] Motac neuroscience, Manchester, UK [2] Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China.</nlm:affiliation></affiliation></author><author><name sortKey="Marti, Matteo" sort="Marti, Matteo" uniqKey="Marti M" first="Matteo" last="Marti">Matteo Marti</name><affiliation><nlm:affiliation>Department of Life Sciences and Biotechnology (SVeB), University of Ferrara, Ferrara, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Morgenstern, Rudolf" sort="Morgenstern, Rudolf" uniqKey="Morgenstern R" first="Rudolf" last="Morgenstern">Rudolf Morgenstern</name><affiliation><nlm:affiliation>Institute of Pharmacology and Toxicology, Charité Campus Mitte, Humboldt University, 10117 Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Sohr, Reinhard" sort="Sohr, Reinhard" uniqKey="Sohr R" first="Reinhard" last="Sohr">Reinhard Sohr</name><affiliation><nlm:affiliation>Institute of Pharmacology and Toxicology, Charité Campus Mitte, Humboldt University, 10117 Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name><affiliation><nlm:affiliation>1] Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [2] CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [3] Motac neuroscience, Manchester, UK [4] Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China [5] Service de Neurologie, Centre Expert Parkinson, CHU de Bordeaux, 33076 Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Morari, Michele" sort="Morari, Michele" uniqKey="Morari M" first="Michele" last="Morari">Michele Morari</name><affiliation><nlm:affiliation>Department of Medical Sciences, Section of Pharmacology, University of Ferrara, Ferrara, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Meissner, Wassilios G" sort="Meissner, Wassilios G" uniqKey="Meissner W" first="Wassilios G" last="Meissner">Wassilios G. Meissner</name><affiliation><nlm:affiliation>1] Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [2] CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [3] Service de Neurologie, Centre Expert Parkinson, CHU de Bordeaux, 33076 Bordeaux, France [4] Centre de référence AMS, CHU de Bordeaux, 33076 Bordeaux, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Scientific reports</title><idno type="eISSN">2045-2322</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects)</term><term>Animals</term><term>Benserazide (adverse effects)</term><term>Benserazide (pharmacokinetics)</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (metabolism)</term><term>Disease Models, Animal</term><term>Dopamine (metabolism)</term><term>Dopamine Agents (adverse effects)</term><term>Dopamine Agents (pharmacokinetics)</term><term>Drug Combinations</term><term>Dyskinesias (etiology)</term><term>Dyskinesias (metabolism)</term><term>Female</term><term>Levodopa (adverse effects)</term><term>Levodopa (pharmacokinetics)</term><term>Macaca mulatta</term><term>Male</term><term>Parkinson Disease (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Benserazide</term><term>Dopamine Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Benserazide</term><term>Dopamine Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term><term>Dyskinesias</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Drug Combinations</term><term>Female</term><term>Macaca mulatta</term><term>Male</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">L-dopa remains the mainstay treatment for Parkinson's disease (PD), although in later stages, treatment is complicated by L-dopa-induced dyskinesias (LID). Current evidence links LID to excessive striatal L-dopa-derived dopamine (DA) release, while the possibility of a direct involvement of L-dopa itself in LID has been largely ignored. Here we show that L-dopa can alter basal ganglia activity and produce LID without enhancing striatal DA release in parkinsonian non-human primates. These data may have therapeutic implications for the management of advanced PD since they suggest that LID could result from diverse mechanisms of action of L-dopa.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24429495</PMID><DateCreated><Year>2014</Year><Month>01</Month><Day>16</Day></DateCreated><DateCompleted><Year>2015</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2014</Year><Month>01</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><PubDate><Year>2014</Year><Month>Jan</Month><Day>16</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.</ArticleTitle><Pagination><MedlinePgn>3730</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/srep03730</ELocationID><Abstract><AbstractText>L-dopa remains the mainstay treatment for Parkinson's disease (PD), although in later stages, treatment is complicated by L-dopa-induced dyskinesias (LID). Current evidence links LID to excessive striatal L-dopa-derived dopamine (DA) release, while the possibility of a direct involvement of L-dopa itself in LID has been largely ignored. Here we show that L-dopa can alter basal ganglia activity and produce LID without enhancing striatal DA release in parkinsonian non-human primates. These data may have therapeutic implications for the management of advanced PD since they suggest that LID could result from diverse mechanisms of action of L-dopa.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Porras</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1] Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [2] CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [3] Motac neuroscience, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Deurwaerdere</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>1] Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [2] CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>1] Motac neuroscience, Manchester, UK [2] Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marti</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Life Sciences and Biotechnology (SVeB), University of Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgenstern</LastName><ForeName>Rudolf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology and Toxicology, Charité Campus Mitte, Humboldt University, 10117 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sohr</LastName><ForeName>Reinhard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology and Toxicology, Charité Campus Mitte, Humboldt University, 10117 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bezard</LastName><ForeName>Erwan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>1] Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [2] CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [3] Motac neuroscience, Manchester, UK [4] Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China [5] Service de Neurologie, Centre Expert Parkinson, CHU de Bordeaux, 33076 Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morari</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, Section of Pharmacology, University of Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meissner</LastName><ForeName>Wassilios G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>1] Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [2] CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France [3] Service de Neurologie, Centre Expert Parkinson, CHU de Bordeaux, 33076 Bordeaux, France [4] Centre de référence AMS, CHU de Bordeaux, 33076 Bordeaux, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C005177">benserazide, levodopa drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>762OS3ZEJU</RegistryNumber><NameOfSubstance UI="D001545">Benserazide</NameOfSubstance></Chemical><Chemical><RegistryNumber>9P21XSP91P</RegistryNumber><NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2000 Mar;74(3):1147-57</RefSource><PMID Version="1">10693947</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Res. 2010 Sep;68(1):44-50</RefSource><PMID Version="1">20542064</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pharmacol Exp Ther. 1975 Dec;195(3):453-64</RefSource><PMID Version="1">489</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Pharmacol. 1986 Sep;89(1):229-34</RefSource><PMID Version="1">3801773</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1989 Jun 26;490(2):332-8</RefSource><PMID Version="1">2765866</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Neurosci. 1990 Jul;13(7):281-5</RefSource><PMID Version="1">1695404</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 1991;44(3):591-605</RefSource><PMID Version="1">1754053</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Pharmacol Sci. 1993 Apr;14(4):119-23</RefSource><PMID Version="1">8100096</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1996 Jan;60(1):36-40</RefSource><PMID Version="1">8558148</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Prog Neurobiol. 1996 Aug;49(5):415-54</RefSource><PMID Version="1">8895995</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroreport. 1999 Feb 25;10(3):631-4</RefSource><PMID Version="1">10208602</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2004 Dec;127(Pt 12):2747-54</RefSource><PMID Version="1">15329355</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Neurosci. 2005 Jul;22(1):283-7</RefSource><PMID Version="1">16029219</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 2006 Jun;22(3):586-98</RefSource><PMID Version="1">16531050</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2007 Feb 7;27(6):1297-307</RefSource><PMID Version="1">17287504</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2010;5(11):e14053</RefSource><PMID Version="1">21124922</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 2011 Feb;41(2):585-90</RefSource><PMID Version="1">21092759</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Drug Discov. 2011 May;10(5):377-93</RefSource><PMID Version="1">21532567</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Death Dis. 2011;2:e154</RefSource><PMID Version="1">21544093</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2011 Oct;26(12):2246-52</RefSource><PMID Version="1">21755537</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 2011 Dec 15;198:245-51</RefSource><PMID Version="1">21840375</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cold Spring Harb Perspect Med. 2012 Mar;2(3):a009308</RefSource><PMID Version="1">22393538</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2012 Sep 15;27(11):1373-8</RefSource><PMID Version="1">22976821</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2012 Nov;122(11):3977-89</RefSource><PMID Version="1">23041629</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2012 Nov 14;32(46):16106-19</RefSource><PMID Version="1">23152595</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Transplant. 2007;16(3):229-44</RefSource><PMID Version="1">17503735</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2007 Jul;130(Pt 7):1819-33</RefSource><PMID Version="1">17452372</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2008 Jan;131(Pt 1):120-31</RefSource><PMID Version="1">17956909</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 2008 Feb;29(2):210-20</RefSource><PMID Version="1">17920284</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2008 Dec;131(Pt 12):3380-94</RefSource><PMID Version="1">18952677</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 2009 Mar 3;159(1):16-20</RefSource><PMID Version="1">19146929</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 2010 Mar 17;166(2):355-8</RefSource><PMID Version="1">20026252</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 2010 Apr;38(1):136-43</RefSource><PMID Version="1">20096781</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sci Transl Med. 2010 Apr 21;2(28):28ra28</RefSource><PMID Version="1">20410529</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Mol Neurobiol. 2010 Aug;30(6):817-25</RefSource><PMID Version="1">20232137</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2003 Jun;9(6):762-7</RefSource><PMID Version="1">12740572</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015632" MajorTopicYN="N">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001545" MajorTopicYN="N">Benserazide</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020820" MajorTopicYN="N">Dyskinesias</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC3893648</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>08</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24429495</ArticleId><ArticleId IdType="pii">srep03730</ArticleId><ArticleId IdType="doi">10.1038/srep03730</ArticleId><ArticleId IdType="pmc">PMC3893648</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000628 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000628 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24429495
|texte= L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24429495" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |